OCEANIA: real-world study of ovarian cancer treatment patterns across multiple lines of therapy in Argentina and Brazil.

Aim: To evaluate real-world data on treatment patterns in Argentina and Brazil in patients with ovarian cancer. Methods: This study evaluated de-identified antineoplastic exposure data from a private healthcare provider in Argentina and health claims database (Orizon) in Brazil from 2010 to 2019 and 2015 to 2020, respectively. Results: Platinum-based chemotherapy was the most common first-line therapy (Argentina: n =311 [87.6%]; Brazil: n = 1142 [79.3%]). The proportion of patients receiving platinum-based chemotherapy declined across both populations from first- to second-line, while use of non-platinum-based, targeted, and hormone therapies increased. Duration of platinum-based treatment and time to next treatment decreased from first- to fourth-line. Conclusion: There is an unmet need for effective therapies that can prolong time to next treatment in ovarian cancer in Argentina and Brazil.

[Box: see text].

Primary Central Nervous System Lymphoma with Exclusive Leptomeningeal Involvement: The Diagnostic Challenge of a Rare Presentation of an Uncommon Disease.

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive extra-nodal non-Hodgkin lymphoma (NHL). It must be confined to the brain, eyes, spinal cord or leptomeninges without systemic involvement at the time of diagnosis. Disease confined to the cerebrospinal fluid (CSF) is a rare form of presentation and poses a particular diagnostic challenge. We present the case of an 82-year-old man admitted to hospital because of an acute confusional state, later revealed to be due to PCNSL with exclusive leptomeningeal involvement. The diagnostic process was further impaired (or, perhaps, aided?) by the onset of a COVID-19 outbreak on the ward. LEARNING POINTS: Primary central nervous system lymphoma is a rare and aggressive form of non-Hodgkin lymphoma.Exclusive involvement of the cerebrospinal fluid (CSF) is a rare form of presentation of PCNSL.The diagnosis is usually histopathological but, in the absence of a solid lesion that can be biopsied, CSF cytology and flow cytometry may be sufficient for a definitive diagnosis.

Eosinophilic Granuloma: A Rare and Often Benign Condition Presenting as a Lump on the Head, which was Easily Treated.

Eosinophilic granuloma is a localized, non-invasive form of Langerhans cell histiocytosis. It usually develops in the long bones and is more frequent in children under the age of 10 years. It is very rare in adults. We present the case of a young woman admitted to hospital for persistent refractory left parietal headache, later revealed to be caused by an eosinophilic granuloma. LEARNING POINTS: Eosinophilic granuloma is a localized benign form of Langerhans cell histiocytosis.It is essential to exclude the presence of bone lesions in other locations and/or systemic involvement.The prognosis is good, with surgical resection, when necessary, being a curative intervention, although sometimes (as in this case) a conservative approach is sufficient.

Proteus Syndrome: A Rare Case in An Adult Ward.

Proteus syndrome is an extremely rare disorder that manifests as an asymmetric, disproportionate overgrowth of any connective tissue, such as bone, fat or epidermal nevi, in a mosaic or patchy pattern. It has an estimated prevalence of less than 1/1,000,000 live births. The diagnosis can be difficult because the phenotypes of the patients are variable. Many individuals develop cutaneous capillary malformation and prominent varicosities (large and complex vascular malformations). Thus, Proteus syndrome patients are at risk of developing deep vein thrombosis and pulmonary embolism. The authors present the case of a patient with Proteus syndrome who was admitted because of pulmonary thromboembolism and presented hypertrophy of the left arm and left hemithorax. LEARNING POINTS: Proteus syndrome is an extremely rare disorder that manifests as an asymmetric, disproportionate overgrowth of any connective tissue.The diagnosis can be difficult because the phenotypes are variable.It is important to keep in mind the importance of anticoagulation because patients are at risk of developing deep vein thrombosis and pulmonary embolism.

Prevalence and outcome of thrombocytopenia in systemic lupus erythematous: single-centre cohort analysis.

OBJECTIVES: We aimed to characterise the frequency of thrombocytopenia in systemic lupus erythematosus (SLE) and determine its time of onset during the course of the disease, and its severity and impact on mortality. METHODS: This was a single-centre cohort analysis of 707 patients with SLE followed for up to 40 years. We reviewed the patients' clinical notes identifying the presence of thrombocytopenia, its time of onset and ascertained other clinical and serological features of the disease. Thrombocytopenia was classified as mild (100-149x109/L), moderate (31-99x109/L) or severe (≤30x109/L platelets). It was also classified as asymptomatic, with minor bleeding or with major bleeding. RESULTS: 22.9% of patients (n=162) had thrombocytopenia prior to or during the course of SLE. Twenty-three patients (14.2%) had isolated immune thrombocytopenia (ITP) before the diagnosis of SLE. Median follow-up time was 19 years (IQR=13). Most patients (n=67, 41.4%) had mild thrombocytopenia. More than half the patients (n=98, 60.5%) developed asymptomatic thrombocytopenia and only 6 patients (3.7%) had major bleeding events in the context of thrombocytopenia. The development of severe thrombocytopenia any time during the course of SLE was associated with an increased risk of death (HR=3.57, p=0.025). Anti-phospholipid syndrome was over twice as common in patients with thrombocytopenia in the cohort. There is an increased risk of death for male patients (HR=3.41, p=0.036) who develop thrombocytopenia and for those who present with concomitant haemolytic anaemia (HR=3.07, p=0.027). CONCLUSIONS: The presence of severe thrombocytopenia (platelets ≤30x109) in patients with SLE is associated with an increased risk of death, regardless of bleeding events. Male patients with SLE and thrombocytopenia have an increased mortality risk, as have those who develop concomitant thrombocytopenia and haemolytic anaemia.

Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity?

OBJECTIVES: Risk factors for thromboembolism in SLE are poorly understood. We hypothesized a possible role for protein C, based on its dual activity in inflammation and haemostasis and on the evidence of an association between acquired activated protein C (APC) resistance (APCR) and high-avidity anti-protein C antibodies (anti-PC) with a severe thrombotic phenotype in venous thrombosis APS patients. METHODS: In a cross-sectional study of 156 SLE patients, the presence and avidity of IgG anti-PC was established by in house-ELISA, and APCR to exogenous recombinant human APC (rhAPC) and Protac (which activates endogenous protein C) was assessed by thrombin generation-based assays. Associations with aPL profile, thrombotic history and disease activity (BILAG and SLEDAI-2K) were also established. RESULTS: Anti-PC were detected in 54.5% of patients and APCR in 59%. Anti-PC positivity was associated with APCR to both rhAPC (P <0.0001) and Protac (P =0.0001). High-avidity anti-PC, detected in 26.3% of SLE patients, were associated with APCR in patients with thrombosis only (P <0.05), and with the development of thrombosis over time (range: 0-52 years; P =0.014). High-avidity anti-PC levels correlated with SLEDAI-2K (P =0.033) and total BILAG (P =0.019); SLEDAI-2K correlated inversely with APCR to Protac (P =0.004). CONCLUSION: Anti-PC occur in patients with SLE, independently of aPL profile, and are associated with APCR. High-avidity anti-PC are associated with thrombosis and with active disease and might prove a novel marker to monitor the risk of thrombosis and disease progression in SLE.

Fracture risk in systemic lupus erythematosus patients over 28 years.

OBJECTIVES: Chronic glucocorticoid use is complicated by osteoporosis and increases the risk of fragility fractures. EULAR guidelines on SLE management recommend reducing chronic glucocorticoid dosage to ≤7.5 mg/day to minimize this risk. We examined the relationship of glucocorticoid dose to fragility fracture risk in a cohort of SLE patients. METHODS: Retrospective analysis of SLE patients attending University College Hospital over 28 years was undertaken. Collected data included consecutive steroid dose, dual-energy X-ray absorptiometry scans and fragility fractures. RESULTS: We collected data on 250 patients with a median of 17 years' follow-up. Fragility fractures were diagnosed in 28 (11.2%) patients and the mean ± s.d. age of first fracture was 51 ± 16 years. A total of 94% received glucocorticoids, the average dose being 6.20 mg/day. Patients with fragility fractures had a lower average daily dose (5.36 vs 6.23 mg/day) but a higher median cumulative dose (25.19 vs 20.96 g). These differences were not significant (P = 0.127 and 0.229, respectively). Some 93% of patients received vitamin D, and 85% received calcium. Cox regression analysis showed older age at SLE diagnosis, osteoporosis and secondary hyperparathyroidism were associated with fragility fractures. Glucocorticoid dose was not significantly associated with the occurrence of fragility fractures. Twenty-two patients with fractures were treated with bisphosphonates, two with denosumab and two with teriparatide. CONCLUSIONS: We found no significant association between glucocorticoid treatment and fragility fractures in our group of patients; however, a prospective study including more patients not treated with CS would be necessary to confirm these results.

Gefitinibe na Primeira Linha de Tratamento para o Câncer de Pulmão de não Pequenas Células / Gefitinib as Non-Small Cell Lung Cancer First Line Treatment

Introdução: os inibidores de tirosina quinase (TKIs - tyrosine kinase inhibitor) são o tratamento de primeira linha no câncer de pulmão de não pequenas células (CPNPC) localmente avançado ou metastático com mutação do EGFR (receptor do fator de crescimento epidérmico - epidermal growth factor receptor). Esta revisão compara o tratamento do CPNPC com o gefitinibe, um TKI de primeira geração, versus o tratamento quimioterápico. Método: foi realizada revisão de literatura com palavras-chave relevantes e análise descritiva dos resultados. Resultados: os pacientes com CPNPC e mutação do EGFR apresentaram melhora da sobrevida livre de progressão (SLP), taxa de resposta objetiva (TRO) e taxa de controle da doença (TCR) em relação à quimioterapia citotóxica. A taxa de eventos adversos graves, eventos adversos que levaram à descontinuação do tratamento e os que levaram à redução de dose foram menores com o gefitinibe. O gefitinibe também foi relacionado à melhora da qualidade devida. Conclusão: o uso do gefitinibe em primeira linha no tratamento do CPNPC com mutação EGFR demonstrou superioridade de eficácia, segurança e qualidade de vida, quando comparado ao tratamento quimioterápico.

Introduction: tyrosine kinase inhibitors (TKIs) are the first line treatment for EGFR (epidermal growth factor receptor) mutated non-small cells lung cancer (NSCLC) locally advanced or metastatic. The aim of this review is to compare the treatment of NSCLC with the first-generation EGFR-TKI gefitinib versus chemotherapy . Methods: a review of the literature was performed using relevant keywords and descriptive analysis of the results. Results: patients with NSCLC and EGFR mutation showed improved progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR) compared cytotoxic chemotherapy. The rate of serious adverse events, adverse events leading to discontinuation of treatment and that led to dose reduction were lower with gefitinib. Quality of life improvement was also related to the treatment with gefitinib. Conclusion: the use of gefitinib as first-line treatment of EGFR mutated NSCLC showed improved efficacy, safety and quality of life when compared to chemotherapy.

Immediate effect of a single anteroposterior talus mobilization on dorsiflexion range of motion in participants with orthopedic dysfunction of the ankle and foot.

OBJECTIVE: The purpose of this study was to determine the immediate effects of a single anteroposterior mobilization of the talus on the active dorsiflexion range of motion (ROM) in participants with different orthopedic foot and ankle injuries. METHODS: This study included 30 male and female participants aged 18 to 50 years with unilateral orthopedic foot and ankle dysfunction. All participants underwent 3 sets of active dorsiflexion ROM measurement in both ankles. Measurements included baseline, post-first treatment, and post-second treatment values. Participants received either joint mobilization or manual contact (control) on the affected ankle. Active dorsiflexion ROM was assessed using a biplanar goniometer with participants in the prone position and 90° of knee flexion. RESULTS: Both groups (joint mobilization and manual contact) showed increased active dorsiflexion ROM. However, the mean difference of dorsiflexion measurements before and after mobilization was greater than before and after control treatment. CONCLUSION: A single session of articular mobilization of the talus did not significantly increase dorsiflexion ROM in participants with orthopedic dysfunctions of the ankle and foot compared with a manual contact procedure.

Influence of scapular position on the pressure pain threshold of the upper trapezius muscle region.

A position of scapula depression will maintain the upper trapezius muscle region in a lengthened position, causing excessive strain. This strain could lead to peripheral nociceptive nerves sensitization in the affected area, changing the pressure pain threshold (PPT). Thus, people with a faulty alignment of scapular depression may have lower PPT levels in the upper trapezius region when compared to subjects with normal vertical scapular position. The purpose of this double-blind study was to assess the influence of scapular position on the PPT of the upper trapezius region in a young healthy population. Fifty two physical therapy students of the Catholic University of Minas Gerais-PUC-Minas, Brazil, with normal shoulder (NS group, n=26, 6 men and 20 women) or depressed shoulder (DS group, n=26, 6 men and 20 women) volunteered to participate in this study. An electronic pressure algometer was used to measure the PPT on the upper trapezius muscle region. The results showed a significant difference between groups, with the DS group (19.0+/-9.0 N/cm(2)) demonstrated lower mean PPT values when compared to NS group (26.1+/-9.6 N/cm(2)) (p<0.01). Our results showed that healthy young subjects with depressed scapula position had significant lower upper trapezius PPT values when compared to subjects with normal scapula position.

Preliminary approach to detect amylolytic and pectinolytic activities from maca (Lepidium meyenii Walp)

O objetivo do presente estudo foi determinar valores ideais de pH e temperatura para avaliar as atividades amilolítica (AM), pectinesterásica (PE) e poligalacturonásica (PG) em raízes de maca (Lepidium meyenii Walp.). Foi utilizado o modelo de superfície de resposta para atingir valores confiáveis de atividades enzimáticas em extratos brutos. Os valores máximos de atividade AM ocorreram em pH 6,1 a 33,6 °C, muito próximos do ponto central dos experimentos. Para as atividades de PE e PG, o valores ótimos foram atingidos em pHs 6,6 e 5,4, a 49,4 e 46 °C, respectivamente.

Alterações pós-colheita em raízes de mandioquinha-salsa (Arracacia xanthorrhiza Bancroft): atividade enzimática, identificação de contaminante e caracterização parcial do amido / Alterations after harvest in peruvian carotovora (arracacia santhorrhiza bancroft) roots: enzymatic activity, pollutant identification and partial characterization of the starch

Este trabalho teve como principais objetivos verificar as alterções na atividade de enzimas amilolíticas, pectinolíticas e celulásicas em raízes de mandioquinha-salsa durante o período pós-colheita, sob diferentes condições de armazenamento, visando avaliar os mecanismos de deterioração das raízes, bem como identificar o microrganismo possivelmente responsável pela alta perecibilidade das raízes. Além disso, foram estudadas características físico-químicas e reológicas do amido de mandioquinha extraído em laboratório. Para a detecção de atividade pectinesterásica (PE) e poligalacturonásica (PG) nas raízes, os parâmetros de extração destas enzimas foram otimizados através de metodologia de superfície de resposta (MSR)...

The aim of this work was to verify the changes in amylolytic, pectinolytic and cellulasic activity in Peruvian carrot roots after harvest, under different storage conditions, in order to evaluate the deteriorative mechanisms of the roots, as well as to identify the microorganism possible responsible to its low conservation time. In addition, physico-chemical and rheological characteristics of Peruvian carrot starch were studied. For pectinesterase (PE) and poligalacturonase (PG) detection on the roots, the extraction parameters of both enzymes were optimized by response surface methodology. The enzymes presented the optimum pH values at 7.5 and 4.0 for PE and PG, respectively. Extraction time and NaCI concentration were considered non-significant by the model. Pectic enzymes seams to be related to the deterioration process of Peruvian carrot, that is associated to the root softening. Considering the high volume of gas under specific packing and temperature, the presence of microorganisms soft rot promoters could be the main cause of the high perecibility of the roots. The amylolytic enzymes present an important role on Peruvian carrot deterioration related to the starch hydrolysis and the releasing of reducing sugars, substrate for opportunistic microorganisms. The cellulasic activity was not significant during storage time. Best conditions for roots conservation occurred at 4°C and under vacuum package. The bacteria isolated from the roots were identified by biochemical reactions as Erwinia carotovora subsp. odorifera. Peruvian carrot...